DOP59 Maintenance of remission with tofacitinib in patients with ulcerative colitis: Updated results of a subpopulation analysis from an open-label, long-term extension study, OCTAVE Open
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjz203.098
Abstract: Tofacitinib is an oral, small-molecule JAK inhibitor for the treatment of ulcerative colitis (UC). Efficacy and safety were demonstrated in 3 Phase 3, randomised, placebo-controlled studies in patients with moderate to severe UC.1 An ongoing,… read more here.
Keywords: octave sustain; remission; study; tofacitinib bid ... See more keywords